Global Relay Intelligence & Practice
All the latest news, insights, and publications from Global Relay.
Latest stories
CMS ends Medicaid and CHIP funding for pediatric gender‑related procedures
New CMS rule bars federal dollars from covering puberty blockers, hormones, and surgeries for minors, citing safety concerns and insufficient evidence.
Is the true cost of subsidising a financial system that does not integrate ESG higher than the cost of one that does? Elisa Forletta discusses.
Federal Medicaid rules exclude homelessness from automatic exemptions, leaving vulnerable populations at risk of losing coverage.
Disciplinary decisions issued July 4 – 31, 2026.
Highlights
Spotlight
Steve Penry on the evolution of energy market surveillance
Related articles
Industries Feed
Podcasts
Compliance
Olivier Chambord tells GRIP about the importance of building protections into complex contracts via strategic risk allocation, host-government agreements, liquidation preferences, force majeure provisions, and more.
Regulated banks can no longer treat Annex 1 regulation as a stamp of compliance.
Governance Market Survey looks into how the governance function has evolved, how it is resourced, and issues with overall attitude and recognition.
The agency is the latest to drop the doctrine pursuant to a 2025 Trump executive order.
Regulation
The DOJ’s Antitrust Division is returning to targeted Second Request investigations.
Regulator urges firms experiencing growth to consider findings and assess whether arrangements remain appropriate.
Our regular roundup of the latest news and developments from the FCA.
FDA sets FY 2027 medical device user fees, updating submission and registration costs under MDUFA V and outlining small business reductions.
Technology
A NYDFS investigation following a ransomware attack uncovered an inadequate cybersecurity risk assessment.
OpenAI provided the first detailed explanation of the Hugging Face incident at the annual cybersecurity conference in Las Vegas.
Overview of EU AI Act transparency obligations under Art 50, and guidance for legal and compliance counsel.
Analysing the compliance imperatives for both US pharma and the strategic considerations for Chinese biotech navigating the cross-border environment.
Get full access, free for a month
Stay ahead with the compliance and regulatory insight you need. Start your 28-day free trial to access all content on GRIP – no payment details required.
What’s included:
- Every new article, plus our 5,000+ archive
- Daily regulatory insight and guidance
- Exclusive interviews and in-depth analysis
- Coverage of industry-leading events and conferences
- All podcasts and videos, featuring industry experts
- The full set of Rules Navigator tools
- An ad-free experience
Energy markets in the spotlight